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ABSTRACT
The Novartis BioPharmOps division is responsible for manufacturing large molecule products, including
monoclonal antibodies, for late stage clinical trials and commercial sales. The BioPharmOps site in
Huningue, France is expanding their product line but is also trying to reduce costs; cost pressures are
increasing as biotech products become a larger part of Novartis' pipeline.
The site uses a standard cost method to calculate their product costs. However, when using standard costs
it can be time-consuming to extrapolate and predict costs when inputs and assumptions (such as product
mix or process parameters) are changed. This project describes development of a model that allows the
factory to quickly and easily simulate new product mixes and process flows. This model provides the site
with a different view of their costs that will help them understand their cost drivers more completely and
thereby help enable strategic decision-making at the site.
A model of this type can be used to provide unexpected insights but the data in it are not meant to stand
alone. By using results from a cost model like this along with operational metrics like throughput time or
changeover time, a site should be able to quickly predict the cost impact of process changes or changes in
the production plan.
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1. Introduction
1.1 Problem Statement
Since Novartis A.G. was founded in 1996 with the merger of Ciba-Geigy and Sandoz, it has grown to be
one of the largest pharmaceutical companies in the world. It employs over 100,000 people and has a
well-developed product pipeline spread across pharmaceuticals, vaccines, and generic drugs. Over the
past few years, the development of biologic products has grown in importance to the company. The
biologics group appears well positioned for the future as well, with a pipeline that comprises about 25%
of Novartis' new development. (Novartis AG)
As growth in biologics continues, the division faces new challenges. One area that will be of particular
importance in the future is costs; what strategies can be pursued to continue to bring costs down? As
belts keep tightening within the pharmaceutical industry, this focus on costs is likely to continue growing.
The focus on costs will extend throughout the product development lifecycle, and one important area
within this is the manufacturing process. Companies would love to reduce manufacturing costs and
receive higher margins. However, before any cost reduction can occur, it is necessary to understand
which factors drive costs in the first place. Like most established companies, Novartis has a robust cost
system in place that is used to value any biotech products already being produced. The system is used
throughout the company and uses a common method for accounting, "standard costing," to track each
division's finances and to report external results. This system, while sufficient for its intended purposes,
was not designed to answer every potential question the division might have about its costs. Therefore, it
can be time-consuming when it is used to predict costs for the future or to do sensitivity analysis of
different scenarios.
The biotech manufacturing sites would like to address some of these challenges and find a solution that
makes it easier for them to take action on their financial results. In particular, Novartis would like a
different way of looking at their costs internally that will enable faster and easier analysis of different
scenarios impacting costs (such as changes to the process or product mix) and will make cost data more
intuitive to understand.
1.2 Hypothesis
As described above, a company's financial results can be difficult to understand and accounting methods
like standard costing add a layer of complexity that is often not understood much outside of the finance
department. The goal of this thesis is to show another way of looking at costs that will address some of
these difficulties.
The thesis describes the development and use of a cost model that provides Novartis with a new view of
their biotech production costs. This cost model uses the same financial data sources as the current system
but aggregates and presents the data in a different way. Using these data, the model quickly and easily
predicts the impact that process changes and new products have on the relevant outputs. For example, the
model makes it clearer which costs are fixed and which are variable, thereby allowing users to focus on
the costs that they can influence. It also shows users breakdown of each cost component so they can test
changes in different variables to see their impact, which provides insight into the importance of each input
parameter. This approach makes it easier to understand the interactions between different cost drivers
than was previously possible. It also makes it easier to connect financial results with operational metrics
that are tracked on the factory floor, which allows management to make educated and proactive decisions.
1.3 Results
Before the model was used, it was verified with several sets of historical results. This verification was
completed for material costs, non-material costs, and allocation parameters. Through this process, it was
shown that the model does give the same results as pre-existing (albeit more complicated) cost models at
the site. Information about the verification process was provided so future users of the model will be able
to find the data sources should they wish to verify their data as well.
The goal of this project was to show how a model of this type could be beneficial. Therefore, the next
step was to provide examples of analyses that the model can complete. Several different scenarios were
investigated. The model was first used to understand the breakdown of overall product costs. These
results showed that fixed costs are a high proportion of overall costs, and within the variable costs the
resins and filters are most significant. The next analysis showed how including a cost for idle time in
overall product costs can produce misleading results. Finally, several analyses were done to show
tradeoffs in various process parameters. For example, a scenario was tested where both the titer and
fermentation time increased. The higher fermentation time will hurt costs, but this analysis showed that,
in this case, the improved titer would have a larger impact and costs would still go down as titer goes up.
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In another example, adding another product to the factory actually causes only a small increase in overall
costs.
Through these results, it was shown that the model can be useful for a variety of cost predictions and
scenario analyses and should be used for more of these in the future.
1.4 Thesis Goals and Organization
The intention of this thesis is to illustrate the background and development of the cost model and also to
explain situations where the model can be used. It focuses on several areas:
* Explain several ways cost data are used by companies today
* Illustrate some challenges associated with this cost data and some potential areas for
improvement
* Describe the cost model as one possible way to address these challenges
e Provide sample results and benefits
By explaining the cost model in the broader context, instead of focusing immediately on just one factory,
it is possible to see how these concepts could apply to other companies and other industries outside of
pharmaceutical.
The thesis is organized into sections that broadly relate to these overall goals.
Chapter 1, the Introduction, describes the problem statement as well as the motivation behind the
development of this cost model. It also provides an overview of the project results.
Chapter 2 starts looking at the Business Context that surrounds the project. It outlines the
pharmaceutical industry and emphasizes several of the features that make the industry unique. The
organization and structure of Novartis are explained, as is the biotech production process.
In Chapter 3, the discussion of the project context is continued; however, this chapter focuses on the
Cost Modeling Context instead of on the industry and company features. It explains the background for
cost accounting methods used in various industries. From there, it explains several challenges with these
methods and some solutions that have been used for cost analyses at other pharmaceutical companies.
The model development is introduced in Chapter 4, the Method section. This section describes the
assumptions and criteria used to develop the model. For example, it illustrates several features that were
integral to making the model successful. It also explains the selection process used to choose the model
software.
Chapter 5 gets into the details of Model Development. It steps through the model layout and explains
the input and output parameters. It also explains what drove the selection of each of these parameters.
The Research Analysis is conducted in Chapter 6. This chapter first shows how the model was tested
and verified. From there, it shares several case studies that provide some sample results.
Finally, Chapter 7 is a Conclusion that ties together the preceding chapters and explains how this
research could be applicable to other areas and industries.
2 Business Context
This chapter sets the context for the cost modeling project. It first provides an introduction to the
pharmaceutical industry. Several factors set this industry apart and impact the model development, such
as very long product development timelines, extensive regulations, and a high level of uncertainty. The
chapter then introduces Novartis as a company and explains where in the company the cost model fits in.
Finally, it describes the production process used at Novartis for the biologic products it develops.
2.1 Industry Background
2.1.1 Industry Overview
The pharmaceutical industry started expanding late in the 19th century (Cosper) and since then has grown
into an established industry with revenues well over $700 billion annually. (Zarur and Fleming)
Pharmaceuticals come in many different varieties but products are commonly distinguished by specifying
whether the drug is on-patent or off-patent and whether the drug is a small or large molecule.
While a product is on-patent, the company holding the patent is allowed to prevent anyone else from
selling it. This allows the patent-holder to protect the value of the drug and to recover the investment
made to develop it. Once a product goes off-patent, it is known as a "generic" drug. Other companies are
now allowed to enter the market so competition increases and margins reduce dramatically. This thesis
focuses on products that are still on-patent, although the methodology developed here could apply to both.
The other distinction, between small and large molecule drugs, does not describe the stage of
development; instead, it describes the type of product. Many common medicines like Paracetamol (a pain
killer) and Tetracycline (an antibiotic) are small molecules. These products are usually smaller than 100
atoms and are created using a process of chemical synthesis. Large molecule products (also referred to as
biologics), which have only been developed since the 1970's, rely on biological growth instead of
chemical synthesis. Factories for these products grow a group of genetically modified cells and then use
those cells as miniature factories to produce the product in question. These products are typically much
more complex than small molecules - some of them have over 25,000 atoms - but biologics often have
enough similarities to one another that several products can be produced using a common platform.
(Genentech, Inc.) Monoclonal antibodies (or mAb's) are a common example of a development platform.
By changing aspects of these antibodies they can treat many different diseases. Therefore, since most
mAb's are produced in a similar way, they can often utilize the same facilities and factories for producing
many products. This sharing greatly reduces risk, time for technical development, and capital investment.
One key feature of the industry is the combination of extremely long and costly product development
cycles with very high risks. A typical product takes 10-15 years and $800M - $1 B to develop from an
early stage idea to a product that is ready for sale (see Figure 1).
Figure 1: Pharmaceutical Product Development Cycle (innovation.org)
Adding to the uncertainty, very few products actually make it through the entire development cycle
because testing often shows that they were not as effective or safe as they should be. For example, for a
typical large molecule product, fewer than 15% of the products entering Phase I clinical trials will end up
being approved by the FDA (Suresh and Basu, Improving Pharmaceutical Product Development and
Manufacturing: Impact on Cost of Drug Development and Cost of Goods Sold of Pharmaceuticals). In
order to undertake research of this scale, a company has to be prepared to shoulder high risk for a
prolonged time period.
2.1.2 Industry Regulation
Another feature that distinguishes pharmaceutical companies from many others is the strict regulatory
environment in which they operate. The drugs they produce can be life-saving to patients that take them,
but they can also be life-threatening if side effects are not understood or if anything goes wrong during
the manufacturing process. Because of these risks, various regulatory agencies audit and monitor both the
initial qualification and the ongoing manufacturing of all products. While this helps ensure that our
medicines are safe, it also means that it can be difficult and time-consuming to make process
improvements in a factory once a product is approved. These restrictions have contributed to the
reluctance of companies to wholeheartedly pursue any cost improvement programs. (Suresh and Basu,
Improving Pharmaceutical Product Development and Manufacturing: Impact on Cost of Drug
Development and Cost of Goods Sold of Pharmaceuticals)
2.1.3 Industry Cost Structure
In part because of the high risks and large investment costs, the pharmaceutical industry has a different
cost structure from many others. For example, the ratio of cost of goods sold (COGS) to sales in the
automotive industry is typically well above 70% (YCharts). In contrast, many pharmaceutical companies
will only spend 27% of their revenues on COGS, and the ratio for biotech companies is closer to 15%
(Basu, Joglekar and Rai).
Understanding this structure helps explain why manufacturing cost reduction has not historically been one
of the primary goals in the pharmaceutical industry. Since production costs were relatively low, it was
more cost-effective and impactful to spend resources elsewhere. Companies would invest extensively in
new research programs but there was less incentive to adopt manufacturing improvements like lean or Six
Sigma. However, several changes in the industry are causing this cost climate to change. First, many key
drugs are going off-patent over the next few years. For example, products generating over $142 billion in
sales will go off patent by 2016 (Zacks Equity Research). These losses mean that many companies will
have fewer products to rely on for a steady revenue stream. In addition, with skyrocketing US healthcare
costs and an increased focus on healthcare reform, the pharmaceutical industry is under unprecedented
pressure to reduce prices. Due to these changes and others, many companies in the industry are starting to
search for cost savings wherever possible. Since manufacturing is an area that has not been a focus in the
past, it has the potential for high savings now. Therefore, the next few years will probably see many more
cost-reduction programs being implemented across the industry.
2.2 Company Background
2.2.1 Company Overview
With nearly 120,000 employees and 2010 revenues of $50.6 billion, Novartis is one of the largest
pharmaceutical companies in the world. (Novartis AG) Historically, the company's focus was on small
molecule products but the past few years have seen growing investment in large molecule products as
well; biologics, including several monoclonal antibodies, now comprise 25% of Novartis' pipeline.
(Novartis AG)
The company is divided into four divisions: Pharmaceuticals, Vaccines and Diagnostics, Sandoz, and
Consumer Health. While each division is connected at a high level, they still operate very independently.
Even within the same division there can be substantial separation between different groups. This project
focused on work with the Pharmaceuticals division (aka "Pharma"). This is the area that does all
development and manufacturing for prescription drugs (both small and large molecules) that are still
patent protected. The project could also be relevant for Sandoz, the division that manufactures generics,
since their methods for calculating costs and some of their production methods are similar to the methods
used in Novartis Pharma.
2.2.2 Organizational Analysis
Research conducted at the MIT Sloan School of Management led to the development of a method for
assessing organizational dynamics within a company. (Carroll) This assessment provides insights into
company standards and behaviors using three different views, or "lenses": the strategic, political, and
cultural lens. These insights can help in understanding the real-world issues that plague implementation
of many projects. Looking at them here sheds light onto the way decisions are made within Novartis and
also reveals (and helps avoid) potential challenges for project implementation.
The strategic view refers to the structure of the company and the way it is organized. For example, as
stated above, Novartis is divided into four divisions. Each division is then broken down further into a
number of different groups. For a simplified layout diagram of the Pharmaceutical division, see Figure 2.
Novartis
Pharmaceuticals
DevelementBioPharrnOps
Factory Factory Factory
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Figure 2: Simplified Structure of Novartis Pharma
The BioPharmOps group shown in this diagram is responsible for process development and
manufacturing for all patented biologic products. The diagram shows how BioPharmOps is distinct from
the Development organization. BioPharmOps owns all of the factories and manufacturing whereas
Development discovers and develops the new products. Nonetheless, the groups still depend heavily on
one another. For example, both Development and BioPharmOps need to use capacity in the
BioPharmOps factories; BioPharmOps uses capacity to manufacture commercial products and
Development needs a way to produce drugs for clinical trials. Since BioPharmOps owns the factories,
Development relies on them to produce this clinical trial material. At the same time, Manufacturing relies
on Development to come up with formulations for all new products.
This structure means that the two groups have to work closely together to manage capacity - and share the
costs - for each factory. Since each group has a different set of incentives and motivations it can be
challenging to determine who should pay for each aspect of production. The key takeaway for this
project is that any model that is developed, in order to be useful, needs to consider the incentives and
needs from both sides.
The cultural lens refers to the customs and standards for behavior within a company. People are
accustomed to talking about the culture of a country, or cultural differences from one country to another,
but each company (or even division) has a culture of its own as well. Cues for cultural aspects of an
organization can be found anywhere. For example, signs posted on the wall, employees' working hours,
or the arrangement of the desks all provide insight into the culture of a group. For example, Novartis
BioPharmOps tends to be a fairly open and un-hierarchical group; it is easy to approach people and ask
for help or to ask questions. This is apparent from peoples' verbal response when you ask to set up a
meeting but can also be inferred from the arrangement of the desks; six or more desks are clustered
together in each office, which encourages a collaborative work environment. Another insight into the
culture's division is found in the languages spoken at the site. Novartis is a Swiss company (located in
the German-speaking area of Switzerland), but the company's official language is English. In Novartis'
French biotech factory, the majority of employees are either bi or tri-lingual. Nonetheless, the language
heard most commonly, and the one used in most wall decorations and site emails, is French. In this case,
learning the local language is one way to become more integrated into the organization. These
observations suggest that the division will be open to new ideas but it may be easier to implement change
if it is done by working very closely with local employees.
The final organizational view, using the political lens, focuses on decision-makers and the control of
information in an organization. As in any large company, decisions and information at Novartis are
spread throughout the organization. Of particular relevance to this thesis is financial data. Novartis is
understandably protective of its financial information. Not only is this data important for overall financial
results but it can also be easily misrepresented; if someone looks at financial results but does not
understand the assumptions behind them, it is easy to draw inaccurate conclusions. Because of these
concerns, any project working with financial data must be carefully managed. These considerations
suggested that the model should be developed in a modular way so it can be shared across the company
without revealing confidential information.
2.3 Biotech Production Process
As described earlier, the production process for small and large molecule products is very different.
Small molecule products depend on chemical synthesis whereas biologic products rely on cell growth.
Despite the complexity of these biologics, the manufacturing process for different products is often
surprisingly similar. For example, monoclonal antibodies share almost all basic steps from product to
product. The function of each antibody may be very different but the fundamental structure is similar
enough that many manufacturing steps and pieces of equipment can be shared.
There are two main stages in this antibody production process. The first stage is Cell Culture, which is
where cells are grown and the antibody is produced. After this stage is completed, the product goes
through the Purification steps where the product is cleaned and filtered. Most products follow similar
sub-steps within each of these broad categories as well, so a company is able to develop each process
much more quickly and can often use a factory for several different products.
This cost model was developed to model an mAb factory that could produce multiple mAb's during a
given year. While the steps for each product are often the same, different process parameters (such as the
material selection or cycle time) impact the product output. The following section describes details of the
production process as well as some parameters that are important to the process reliability, efficiency, and
cost.
2.3.1 Cell Culture
The cells used during production are essentially miniature factories for the mAb product. To begin
production, the company creates a "master cell bank", or a group of cells that have been encoded with
instructions for producing the antibody. During cell culture, the product proceeds through a series of
steps where cells are grown and then antibody is produced. (Abu-Absi, Yang and Thompson) There are
two common types of cell culture production, called fed-batch and perfusion; this model is designed for a
fed-batch process.
Inoculation: Cells from the master cell bank have been replicated and are now used to
start production of each new batch.
Cell Culture: After the batch is begun, the cells are given food so they can grow and
multiply. More food is added regularly and cells are transferred into larger vials and
tanks as they grow. Once the final tank is reached, the cells stop dividing and produce
the mAb. At the end of the cell culture process, factory workers measure the
concentration of product in the tank, commonly referred to as the titer. This is a key
parameter since it largely defines how much product will be obtained from each batch.
Harvest: The drug substance is removed from the final tank and sent through a
centrifuge. During this step, the product (the antibody) is saved and the larger pieces
(cells, DNA, and other remnants) are discarded.
2.3.2 Purification
The final drug substance must not contain any impurities. The goal of the purification steps is to isolate
the antibody and remove all unwanted materials. (Kelley, Blank and Lee, Downstream Proce'ssing of
Monoclonal Antibodies: Current Practices and Future Opportunities)
Clarification: The solution is filtered for the first time. Many filters used during
purification steps are expensive and comprise a significant part of the production cost.
Protein A Chromatography: The solution is run past a special material called a resin.
The product attaches to the resin and is saved while much of the debris, not captured by
the resin, is discarded. Each batch of Protein A resin can be used for multiple batches of
product before being discarded but it is still one of the most expensive materials used
during production.
Chromatography 2: A purification step with a new resin removes additional impurities.
Chromatography 3: A third chromatography step removes even more impurities. The
resins for Chromatography 2 and 3 are still expensive but they are far less significant than
the Protein A resin.
Ultrafiltration / Diafiltration: The substance is filtered one final time and the product
concentration and composition are adjusted. Filters used during this step can also be
costly.
Final fill: The solution is frozen so it can be put into vials or syringes at a later time.
2.3.3 Batch Production
Although the production process is similar from product to product, it is challenging to run different
products in a factory at the same time. Therefore, products are run in campaigns, where several batches
of the same product are run in sequence before switching to the next product. When one campaign is
coming to an end the factory completes a changeover and initiates production for the next product.
The raw materials and consumables described above, such as food for the cells or filters for purification,
are a substantial component of the production costs. However, a large part of the cost comes from
overhead expenses for the many non-material costs. For example, the factory equipment is expensive and
needs to be paid for, as do direct labor and support personnel working at the site. These factors are
investigated in later sections and will be considered alongside material costs in the cost model.
3 Cost Modeling Context
Reporting a product's cost seems like it should be straightforward; calculate what was spent for all
individual cost components (such as raw materials, consumables, depreciation, and labor), add them up,
and you should know how much your product costs. Unfortunately, implementation is much more
complex than the theory and tracking and allocating the extensive data required for this process is a
formidable task. By reviewing some literature relevant to this topic and by examining practices in use at
companies today, this chapter describes a method commonly used for cost accounting today as well as the
history that led to the this method's implementation. Looking at the questions these studies are designed
to answer helps explain what data companies use to make decisions. From there, the chapter explains
what some of the gaps are: what information do companies want from their cost data that they cannot
currently acquire without an extensive and in depth study? These gaps are usually not due to a
misunderstanding or misuse of a company's financial data. Instead, they often arise because we try to use
the system for something it was not intended to do. The final step is to explain how the cost model can
help bridge the gap between the data that are currently available and the questions that companies would
like to answer.
3.1 Current Cost Accounting Method
Like many companies, Novartis uses a method called "Standard Costing" to evaluate and report their
costs. There is substantial literature related to the development and use of this method. Essentially, the
theory behind standard costing is that a manufacturing company establishes a standard - or expectation -
at the beginning of the year for the amount they plan to spend. Using a "standard cost" and a "standard
quantity", they then predict what they expect to spend for the year. These standards are related to the
expected inputs they will use during production. (Baggaley and Maskell)
One important aspect of standard costing is related to allocations. Some components of cost are easy to
attribute to a specific product. For example, money paid for the reagents used to make a batch of product
should clearly be a part of the product's cost. However, many costs are harder to determine. For
example, in a factory that produces 10 different products, which product should bear the cost for the
factory manager? Standard costing allocates these indirect costs to different products using different
allocation keys. Ideally these keys are based on the actual amount of time that the manager spends on
each product but it is hard to get the allocations to be completely accurate.
During the year, as product is produced, the site "absorbs" costs. The goal at the end of the year is to
have absorbed 100% of the costs. However, a company never ends up producing or spending exactly
what they expected. Instead, they have "variances" from expectations. These variances take many forms
(such as an "efficiency variance" or a "price variance"), but they all reflect the idea that actual spending
was different from expected. If variances are high, companies often spend a significant amount of time
and focus tracking down the potential root cause. (Crosson)
3.2 Current Pharmaceutical Cost Studies
Standard costing is a system that was developed for use by the finance group to calculate product costs for
external reporting. However, employees outside of the finance group make many cost-based decisions
that rely on financial data as well. In many cases in the literature, the required data were not readily
available and a new model or analysis was completed in order to aid with these decisions. In particular,
there are three areas addressed in the literature that are of particular relevance. First, there are many
studies into the impact that specific process parameters have on results such as run rate, COGS, or
capacity utilization. Second, there are several studies that look at the future of capacity utilization in
biotech and discuss its importance for costs; these studies emphasize the importance of looking at overall
results and of relating financial performance to operational metrics. Finally, there is research into the
software tool that is most useful to address these questions. This chapter reviews each area and refers to
some representative papers that describe them.
Impact of Process Parameters on Costs
Various studies try to predict the impact that changes to a specific parameter will have on a factory's
overall results. For example, an article by Suzanne Farid evaluates many parameters impacting
downstream costs. For example, she examines how titer, downstream yield, and batch success rate could
drive costs. (Farid) Another article discusses how optimization depends on both yield and run rate.
(Han, Nelson and Tsai) Articles like these try to break down the impact of different cost drivers so
employees can understand which factors to influence.
Relating Financial and Operational Metrics
When management looks at the cost of a product, they tend to look at the overall product cost, including
any overhead that is allocated to that product. However, that view can be misleading. When a new batch
is run, the actual additional cost to a factory tends to be much lower than the overall product cost would
imply. This problem leads into the theme of the next group of articles: the importance of seeing the
overall picture instead of focusing in on just one cost. For example, the article mentioned above by Han,
Nelson, and Tsai talks about the tradeoff between higher material costs and higher overall costs. It
emphasizes that sometimes a higher material cost will lead to better overall results. "Trends in Capacity
Utilization" reflects the difficulty of looking at only financial results because often the risk of running out
of capacity is a much higher concern. This perspective highlights the point that financial and operational
results should be viewed together. (Langer) In "Improving Pharmaceutical Product Development and
Manufacturing," the authors discuss how up front investments in process development can lead to
manufacturing savings down the road. (Suresh and Basu, Improving Pharmaceutical Product
Development and Manufacturing: Impact on Cost of Drug Development and Cost of Goods Sold of
Pharmaceuticals)
Software Selection
Finally, several articles discuss the development and selection of a software package. For example, one
study evaluates the two most common biologic process simulation programs, Aspen Batch Plus and
SuperPro, in eight performance categories. (Shanklin, Roper and Yegneswaran) Another paper analyzes
the choice of production method using a "decision support tool." (Lim, Washbrook and Titchener-
Hooker) A final study uses Excel and a process modeling software tool to analyze downstream
operations to predict whether new operations will have to be developed to meet capacity requirements.
(Kelley, Very Large Scale Monoclonal Antibody Purification: The Case for Conventional Unit
Operations) These studies all show the tradeoffs between using different analytical tools.
3.3 Gap between Available and Required Cost Information
The companies who completed the research described in the previous section may not have stated it
explicitly but they implicitly recognized the challenge addressed by this cost model: there is a dichotomy
between data calculated for financial reports and their operational metrics. Although they each approach
it from a different direction, each article reflects the need for additional modeling and testing that can be
used to make informed decisions.
There is nothing inherently wrong with standard costing. It compiles data in a way that is useful and
relevant for certain types of manufacturing. However, in many environments it will provide contradictory
incentives. In these cases, standard costing causes several problems.
This section outlines the history of some cost accounting systems and then uses scenarios and examples to
describe some of the relevant challenges.
3.3.1 Cost Accounting System Origins
Cost accounting systems as they are known today developed in the early 1900's and were used to value
the worth of a company. At the time, this was a simple process. Most companies made just one product
and that product would only contain a few components. Since then, part complexity has grown by several
orders of magnitude and the valuation process has evolved along with it. Financial systems today are
governed by an extensive set of rules to ensure that all public companies report their results accurately
and fairly. There are a variety of methods that companies can use to value their inventory and assign
costs to each product. However, whether a company uses activity-based costing, standard costing, or
something else, the end goals are the same: to know where money is being spent and how much money is
being earned. (Huntzinger)
These systems were originally created to report companies' results externally, but since products were so
simple this same data could easily be used for internal management to make decisions as well. However,
as product complexity increased, this became increasing difficult. To explain some of these difficulties,
we look at several simple case studies.
3.3.2 Challenges with Cost Accounting Methods
These hypothetical examples may sound familiar to many employees since they arise in companies and
industries around the world. These concepts provide the foundation for the creation of the cost model.
Scenario 1: A manager in a factory generally has good performance but continually has
high variances and cannot figure out how to reduce them.
Root Cause 1: The manager may be performing well but there is a good chance that he finds the
financial results difficult to comprehend and hard to take action on. The variance terms in the
financial report do not make sense to him since they are not connected to the operational metrics
he manages. In addition, he does not even have control over about 60% of the budget items in his
department; these items were allocated to him from a different group. He would prefer to spend
time improving items he already understands and knows how to fix.
Scenario 2: A factory has met all customer demand for the year but they are told by upper
management to produce extra batches in December so they can absorb their remaining overhead
costs and meet their annual financial targets.
Root Cause 2: The customer demand (and therefore the amount of absorbed costs) may have
changed, but the factory's cost targets and variance calculations have not. By producing more,
factories are able to absorb more of their costs and reduce their variances, but they also have to
produce unneeded materials and carry extra inventory.
Scenario 3: A division chooses to outsource a product even though internal capacity is available
and variable costs are low.
Root Cause 3: The table below (Table 1) shows one way this could happen. Both the internal
and external groups would have expenses of $1,000 if they received the contract. They charge
$6,000 and $5,500 respectively since these are their "total costs" for producing. If internal
capacity is available then the best decision for the company would be to produce internally.
However, that decision is obscured by the cost calculation because the company is only looking at
their product cost calculation instead of their overall value stream cost.
Table 1 : Production Cost Options
OptionPo_ _ _
Variable Cost $1,000 $1,000
Fixed Cost $5,000 $4,500
Total Cost to Division $6,000 7;7
Total Cost to Company $5,500
Scenario 4: A manufacturing site would like to lower new product costs by changing some
process parameters but cannot figure out how to explain to the development organization that the
investment in process improvements is worthwhile.
Root Cause 4: Financial results can be confusing for someone to understand without the right
background knowledge. In addition, the financial system is designed to be reactive rather than
proactive. Most financial accounting systems are designed explicitly to report results, which
means by definition that the results have already happened. Management would like a tool that
can predict financial performance if certain process or product parameters change, a goal which
was never expected when the system was designed.
In all of these cases, the players involved (both in manufacturing and in finance) are trying to make the
correct decisions for the business but there is a conflict between the decisions they would like to make
and the indicators available to inform those decisions.
Keep in mind that companies are not automatically making poor decisions just because the financial
systems are not designed to report data in a certain way. There are many reasons that financial analysis is
done the way that it is that are not discussed at length in this thesis; this data is essential for many aspects
of financial control and reporting. In addition, it is still possible to avoid many of the conflicts described
above, even without an entirely new cost system. Employees in finance are often aware of these conflicts
and can take steps to reconcile and reduce some of the differences between groups. Nonetheless, these
issues still arise frequently and it is important to watch out for them. In addition, by analyzing and
compiling the financial data in a different way it is possible to address these struggles more directly and to
make it easier to get the right measurements when they are needed.
3.4 Bridging the Gap with the Overall Cost Model
As described above, there are several specific challenges that arise from using the same financial method
for both external and internal financial results. In particular, several issues stand out:
Results that are hard to understand and take action on: Standard costing calculations lead to
variances which can be hard for managers to relate directly to their business and results. Budgets
also include many costs over which managers have no control.
Conflicting metrics: Financial data reveals only part of the picture. If the finances are not
reviewed alongside the operational metrics such as capacity utilization and product demand, then
each set of metrics will pull managers in different directions.
Focus on product-specific instead of overall costs: A factory that focuses on each product in
isolation runs the risk of optimizing one at the expense of the others. Managers should look at the
impact on their overall costs when they are considering any changes.
Metrics that are reactive instead of proactive: It should be possible to easily analyze several
different scenarios in a factory and get a prediction for their impact on costs.
These challenges are especially daunting in the pharmaceutical industry where the cost of manufacturing
is a low percentage of overall costs and regulatory hurdles are extremely high. However, manufacturing
is an area with much potential for improvement and is a powerful lever that companies can pull to
increase profitability. Therefore, especially in a time of increased focus on cost reductions and efficiency,
these hurdles can be overcome.
This thesis presents one tool to address some of these concerns. It focuses on providing a different view
of costs that makes cost analysis easy and predictive. A customized cost model will allow the site to
intuitively understand their costs and where they come from, and also to predict the potential cost impact
of process and product changes. By understanding their finances and knowing how to take action on
them, managers will be able to make more educated and holistic decisions.
4 Method
Now that the context and drivers for the cost model are understood, it is time to discuss the
implementation. As previously described, the goal of this model is to provide an easier and more intuitive
way to understand costs that helps predict the cost impact of product and process changes. However,
there will be many users whose interests and goals span a wide range of topics. Creating a model that can
address such a variety of users' needs requires a balance of many components. This chapter describes
several critical design features that were considered during model development, including selection of a
software package, and reviews the main assumptions that impacted the model.
4.1 Model Considerations and Goals
Financial results depend on decisions made at all levels of a factory and stakeholders use this financial
data for a multitude of purposes. For example, a financial planner at headquarters might analyze how
much it would cost to produce a few more batches next year; a capacity analyst calculates the return on
investment for choosing to produce in one factory versus another; a tool operator does not even realize
that the extra piece of tubing he uses for every batch is costing the company thousands of dollars per year.
Each employee makes decisions that influence the final cost of the product that is produced and being
able to understand the impact of those decisions can help employees work more effectively.
On the other hand, financial data are incredibly complex. A factory may track their work by dividing into
dozens of cost centers, each of which includes hundreds or thousands of lines of expenses. Behind each
expense is a person or team who is responsible to choose how and when to spend that money.
Forecasting budgets, calculating variations from the plan, and keeping groups on track are not easy tasks.
How does this impact the cost model? The financial data are often managed and kept within the financial
groups due to some of the challenges and complexity described above. However, one goal of this model
is to make these data accessible and understandable to a broader community. Therefore, somehow the
complex financial data have to be presented in a way that the financial planner, the capacity analyst, and
the tool operator can all understand and relate to their jobs - and it has to do this without requiring much
setup and without distorting data.
A few guidelines were established to keep the model focused and to ensure that these requirements would
be met. These were drawn directly from the hypothesis explained in chapter 1: the model must be quick
and easy to set up, it must provide intuition about the various cost drivers, and it must help connect
financial and operational metrics. The following paragraphs summarize these considerations. Later,
when the model is described in more detail, we discuss how these requirements were met.
4.1.1 Easy to Use
A model that confuses its users will not end up being used or, even worse, is likely to be interpreted
incorrectly. A central principle for this model is its ease of use.
In practical terms, that translates into several criteria. For example, calculations in the model should flow
logically from one place to the next. In other words, it should be clear where the user is supposed to input
data and where they look to find the outputs. This reduces the time that users have to spend looking for
input parameters and, since many input parameters are grouped together, it reduces the risk that a
parameter will be missed.
It also means that different users should be able to see clearly which inputs they are responsible for. The
finance group understands the budget data very well but they are not expected to be experts on the process
flow information. The process development group has an opposite view; they understand process
parameters such as product concentration, filtering speed, and material selection but they are less involved
with fine details of the budget. The groups have to work together to supply the model inputs but they
should only be held responsible for their area of expertise. This separation of knowledge led to
development of the model in two separate cost models that tie into one another: the "Process Flow Cost
Model" and the "Overall Cost Model." This design makes it clearer which users should set up which part
of the model and reduces confusion as users learn the model for the first time.
4.1.2 Provides Intuitive Results
After all inputs are entered, users want to use the model to draw conclusions. Like the inputs, these
results should be easy to understand.
When standard costing is used, COGS is reported as a base number with variances added to it. These
variances could include a purchase price variance, a labor variance, a materials usage variance, and more.
On the other hand, when standard costing is not used, COGS can be reported directly as a sum of the
individual components. Although in theory the variances help focus on specific changes from a
company's plan, in practice the root cause of a variance is often extremely difficult to track down. (BMA
Inc.)
The results in this model are reported in a different way that avoids the use of variance. The meaning of
the results is the same as that obtained using standard costing but this method of reporting makes it easier
to relate to operational metrics on the factory floor. Therefore, this model uses simple metrics like
"material costs" and "labor costs" that are more easily adopted as a common vocabulary and can facilitate
communication between groups.
Again, we should emphasize that neither set of results is incorrect; they are just used for different
purposes. In this case, the second set is more applicable for the goals of this model.
Another way to make costs intuitive is through their presentation. The model should not have a lag time
for calculations, so all calculations are done automatically whenever the user updates any parameters.
Next, the most relevant results are presented graphically; these graphs also update automatically
whenever anything changes. Finally, several input options allow the user to compare several scenarios at
the same time. This allows them to do side-by-side cost comparisons extremely easily.
4.1.3 Connects Finance and Operations with the Right Data
It is good to have easy-to-understand inputs and results but without the right data these features are
meaningless. This is perhaps the hardest feature to get right. Again, how do you get the financial
planner, the capacity analyst, and the tool operator all aligned, and how do you give them all the same
incentives so poor decisions are not made? This section explains how the "right data" was chosen to
include in the cost model.
Fixed versus Variable Costs
When calculating costs for a manufactured product, it is clear that these costs include materials and
consumables. For example, biologic product costs should include the cost of food for the cells and the
cost of filters used up for a given batch. These are variable costs and the expense to the factory increases
in direct proportion to the number of batches. In general, some element of fixed costs is also assigned to a
given product's cost. For example, if a product runs in the factory for two weeks, then two weeks' worth
of equipment depreciation is assigned to the product. When new batches are added, the overall cost to the
factory changes by the amount of the variable cost multiplied by the number of batches.
At Novartis and at many other companies, the division between fixed and variable costs is not as clear as
it might sound. For example, producing a batch might be very energy intensive but you also need to
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provide electricity to the factory even if it is shut down. In that case, how much of the utilities cost is
actually variable and how much is fixed? A similar question applies to direct labor. As the number of
batches increases, are additional personnel hired or does the scope of work for the current personnel
simply increase? The diagram below represents the process of examining costs at the Novartis factory,
some of which were assumed to be fixed, and breaking them into smaller pieces to pull out elements that
were actually variable.
Figure 3 : Determining Variable Costs (VCs)
One other consideration is the timeframe being examined. Some costs might be fixed in the short term,
such as the salary for the site manager at a plant. However, long term it is possible to close the factory
down, in which case the factory's fixed costs would reduce to zero.
Since the goal of this cost model is to help managers understand their costs and have more control, it is
important to hone in on variable costs so managers can understand conceptually which products are really
incurring higher costs. Therefore, this model provides several different views of output, one of which
explicitly lists all costs that are variable. The Assumptions section later in this chapter will explain how
the variable costs were selected for this model.
Cost of Idle Capacity
The capacity utilization at a factory will change from year to year and sometimes even from month to
month. In some types of cost reporting, costs for any idle capacity are included in the product cost. This
means that factory overhead costs are distributed across the products being run. Supposed that three
batches are run in the factory but the plant's capacity is four. In this case, capacity utilization is 75% and
the factory could add one more batch without incurring any additional fixed overhead costs. The figure
and table below illustrates this example.
Capacity= 4 batches
OR
Idle Allocated IdleSeparate
Figure 4 : Different Allocations of Idle Capacity
Table 2 Impact of Idle Capacity on Costs (plant capacity = 4 batches/yr)
#battles3 3 4
_________ e kl Ioca d le Sepwt No Weallie Alloasted desparate lsil
Overall factory overhead $1,000 $1,000 $1,000
Overhead per batch $333 $250 $250
Varable cost per batch $500 $500 $500
Total varable cost $1,500 $1,500 $2,000
Product cost $33 $M5 $750
Value strean cost $2,500 $2,500 $3,000
In this example, one result stands out: when idle time is allocated across the products, it looks like the
product gets cheaper when capacity utilization goes up. However, the actual work and expenditure per
product has not changed. This discrepancy can lead to situations where managers believe their product
costs have changed when in reality it is only the plant utilization that is different.
For this model, we decided to report the idle costs separately so that managers could understand the actual
incremental cost for a product. If they determine to allocate those costs later on then they can do so as a
quick secondary calculation.
Value Stream Costs versus Product Costs
The method of allocating idle time described above is not strictly incorrect. Running a batch really does
require the use of the factory's equipment, and if those three batches were not being run then the entire
factory would not be needed. In that case, closing the factory would save a large amount of money.
However, this view can be misleading. The table above (Table 2) also includes a line called "value
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stream cost," which refers to the overall cost of running a product. Looking at a product's value stream
instead of batch by batch costs encourages a high-level view and allows managers to see the interaction
between different cost drivers. Several of the articles reviewed in chapter 3 focused on this challenge. As
they discussed, it is important to see how various drivers, such as run rate and yield, interact with the
costs. This method of looking at overall costs instead of product-specific costs can be very effective but
is still not widely adopted; product costs are used too extensively for things like transfer pricing and cost
per unit calculations. Nonetheless, having both views available requires only a few additional
calculations once the data are available and can reveal interesting insights. Therefore, this model reports
both product by product costs as well as overall costs.1 By including both views of data, users can decide
which one will be most relevant and can hopefully avoid some misguided decisions. In the example
where the manager decided to outsource his product even though internal costs would have been lower, a
view like this could have helped him make the most appropriate decision.
4.2 Assumptions
Cost calculations are complex because they are influenced by many factors. To make a cost model
feasible, these calculations have to be simplified. Simplifying the model and focusing on the most
important elements helps in two ways. First, it allows the model to be easier to use; by choosing the
correct assumptions, this ease of use can be accomplished without sacrificing too much model precision.
Simplification also ensures that model users can understand where results come from and which factors
influence them.
Many assumptions were used in the model to achieve these goals. This section describes the most
relevant assumptions that were made.
Allocation of Fixed Costs (Overhead)
Many costs in the factory are not related directly to a specific batch or product. Instead, these costs are
related to general overhead that is needed to run the factory. The high cost of overhead is especially
1 The overall costs reported in this model are not strictly the same as value stream costs. A true value stream will
include all aspects of product creation, spanning all the way from raw material acquisition to customer receipt of the product.
The overall costs described here only include factory costs and, most notably, do not include any revenues from product sales.
Nonetheless, this approximation will still give insights as a starting point for analysis; this can be extended as the results prove
useful.
apparent in the pharmaceutical industry where there are extensive regulatory requirements that a company
needs to satisfy. For example, support groups (such as HR and Finance), some research labs, costs for the
cafeteria, and salaries for site management are generally unrelated to specific products that are run. To
come up with overall product costs, companies typically use an allocation key to assign a percentage of
overhead costs to each product. They then add this amount to their variable costs to get a total product
cost. (See Figure 5 for a visualization of the product cost components.)
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Figure 5: Representation of Product Cost Components.
The total cost is calculated by adding the cost for materials (e.g. buffers andfoodfor the cell), other
variable costs (e.g. direct labor), and the allocatedfixed costs (e.g. a percentage of equipment
depreciation).
The "Model Considerations" section above reviewed several ways that allocations can be misleading.
However, since cost allocations are still used at Novartis for product cost calculations, a method was
needed to allocate costs in this model.
The goal for a cost allocation is that it be as accurate as possible while not requiring much additional time
for data collection. In this model, a simple assumption was used: the amount of overhead allocated to a
given product was directly proportional to the percentage of the year that this product used the factory.
Allocating it this way is a simple yet understandable method to approximate where overhead costs come
from.
The model does not just look at the way costs vary from product to product. It also reviews the way costs
are distributed across different process steps within a batch. Therefore, costs had to be allocated within
36
batches as well. This allocation was done with slightly more granularity. The Novartis factory has
already compiled data on the average number of labor hours and equipment hours that are required for
each process step. Using these data, it was possible to allocate those particular overhead expenses (for
direct labor and equipment depreciation) to each process step based on the number of hours it takes to
run. This method is not perfect - the data for the labor and equipment hours has some variability in it,
and there are many other factors that influence how costly a process step might be - but it is a good
balance of simplicity and accuracy.
Because no allocation method can be completely accurate, these allocated overhead costs were reported
separately in the model results from the variable costs. This allows model users to look at the data that
they find most relevant.
Variable Costs
Variable costs were calculated based on the number of batches run. Since these could be calculated more
directly, they did not have to be allocated to a given campaign. Understanding which costs are fixed and
which are variable (that is, which ones will increase or decrease in relation to production volumes) is a
critical distinction to understand.
The cost timeframe is also relevant. In some cases, costs may be fixed in the short term but variable in
the long term. For example, a factory that is open this year will have a utilities charge whether it is
producing medicines or not. However, in several years that factory could be shut down and would no
longer have any charges associated with it. For this model, we assume that a cost is fixed if it will not be
changed during the next year.
For this model, two categories of expenses were determined to be purely variable: raw materials and
consumables. The consumables were broken down further into resins (an especially expensive
consumable used during production) and non-resin consumables. These variable costs scale in direct
proportion to the number of batches that are run.2
2 The resin cost is actually not completely proportional. Each resin can be used for multiple batches. When many
batches of a product are run, the resin will be used up completely and it is accurate to assume an average cost for the resin per
batch. When only a few batches are run (for example, when a product is part of a clinical trial), the resin may have extra capacity
left when the product is completed and the resin is discarded, which then increases the apparent price per batch. To account for
these changes, one of the input parameters is related to the number of batches that will be run with each resin.
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Many other expenses, such as depreciation for the factory building, are clearly fixed in the timeframe
used for this model. However, for some costs, like direct labor, it is harder to understand how much of
the expense is fixed and how much is variable. A more detailed description of costs for direct labor,
utilities, and quality follows below.
Variable Cost: Direct Labor
Calculating the number of people needed to run a campaign requires an extensive amount of detail. For
example, to calculate it exactly, you could count the exact number of hours that each person spends on
each product and then assign wages for those hours to that product cost. Any hours that were used for
general tasks could be split evenly across the different products. However, what would you do with hours
where the employees did not have much work to do? Can you hire or fire employees? And how do you
collect all of these data reliably? This process of assigning personnel costs is a challenging task and, in
the end, may not be accurate enough to really be worthwhile. For example, if one product requires fewer
personnel hours than another, it does not mean that the factory will lay off workers for just the few
months while this product is being produced; they still have to pay the workers who are doing less work.
On the other hand, the factory may decide to hire a few temporary workers if one product is significantly
more time-consuming than another.
Understanding the complete impact the number of batches and product selection have on the personnel
costs could be the subject of future research. For this model, a simplified model was used that will at
least give management an idea of the personnel costs. If these costs are determined to be important, it is
possible to adjust the assumptions in the future.
The model assumes that at a certain "Standard" number of batches every year, the user knows the
percentage of the labor force that is variable. For example, the graph below represents a scenario where
running 40 batches in a year means that 10% of direct labor will be variable (Figure 6). When there are
zero batches run in a year, it is assumed that all remaining employees are required and are unrelated to
production volumes. Therefore, at zero batches per year, 0% of the labor force is variable. By using
these assumptions, the direct labor costs for different product levels can quickly be calculated. The input
table on the left is included in the cost model to allow users to change those assumptions.
Figure 6: Projected Direct Labor Costs
Variable Cost: Quality Control and Quality Assurance
Quality costs in the pharmaceutical industry are high due to the importance of making sure the product is
safe and the extensive regulations to ensure compliance that go along with that. This model assumes that
the amount of money and time spent for quality checks on each product is proportional to the amount of
time the product takes to run in the factory. This assumption is a large simplification. Some products
clearly consume more resources in the quality department than others. For example, every time there is a
deviation (or unexpected event) the quality group has to investigate it. Deviations are raised for nearly
every small change and usually they do not have any impact on the product quality. However, to be sure,
the quality group has to investigate them. Some products have just a few simple deviations every week
whereas others have over a dozen more complicated deviations. Those more complicated products
consume significantly more time and money in lab tests and equipment. However, focusing in and
understanding exactly which product consumed how much money was not the focus of this thesis.
Quality costs are under 10% of overall costs and, while this is certainly significant, it could take hours of
manual data collection to understand exactly how much of this budget was used for each product. For
this version of the cost model, that investment was determined not to be worthwhile. In the future, this
could be an area for further investigation and an added level of detail.
Variable Cost: Utilities
There are four main utilities used in the Novartis biologics factory each month: water, wastewater, steam,
and electricity. For each of these, the engineering group has data on monthly expenses for the past
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several years. By comparing these historical data to historical production levels, it was possible to link
utilities costs to the production level. There is some variation from this average, but the historical level
gives a point to start from and the model is set to follow the historical trend exactly.
Batch Consistency
It would be interesting to see how much is really spent on each batch and to see how expenditures change
from batch to batch. However, this cost model is focused on average and expected costs. Therefore, in
this case, the model assumes that each batch is consistent and costs are the same from one batch to
another. Some operational metrics already collected in the factory can be used more precisely for this
type of batch-to-batch tracking.
4.3 Model Software Selection
Several options exist for cost modeling software, some of which were introduced earlier in Chapter 3.
This section focuses on the details of four software packages: SuperPro, Aspen Batch Process Developer,
BioSolve, and Microsoft Excel. It explains how their capabilities differ and then explains why Microsoft
Excel was chosen for this project.
4.3.1 SuperPro
Along with Aspen Batch Process Developer, SuperPro is the most functional of the software packages. It
is a customizable biotech process flow software that allows the user to input details about each step in the
process. It gives the user a multitude of options and has been tested extensively on a variety of products,
in particular monoclonal antibodies. For example, it has models for over 140 unit operations, material
and energy balances, and equipment sizing modules, built directly into the software. Since it is more
customized, it does have a longer learning curve and is more complex than some of the other options.
(Intelligen, Inc.) This software was used once in the Novartis factory several years ago but the intern who
used it is no longer at the company; it has not been used since then and his project was not continued.
4.3.2 Aspen Batch Process Developer
Aspen Batch is similar to SuperPro in that it is customized biotech software. (Aspen Technology, Inc.)
For a detailed comparison of these two programs, see the article titled "Selection of Bioprocess
Simulation Software for Industrial Applications" (Shanklin, Roper and Yegneswaran). As seen in this
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article, Aspen Batch has several differences from SuperPro but "economic analysis is a strength of both
software packages;" it would probably be possible to use them both to acquire the desired cost model
information. The Novartis site has not used this software before but they do have plans to implement a
new process flow model using it in the near future.
4.3.3 BioSolve
BioSolve is an Excel-based program that models the cost of monoclonal antibody processes. Since it is
Excel-based, this software would have fewer capabilities than most other options but it would also be
easier to use. It was not able to analyze multiple different products run in a factory at a time; each
product analysis would have to be conducted separately. One additional benefit is that it includes
databases with common data sets that you can compare to, so when a site does not have the data they
could use the commonly accepted value. The learning curve would be lower than Aspen Batch or
SuperPro, as would the cost.
4.3.4 Microsoft Excel
The final option was to design the software from scratch in Microsoft Excel. This would not have as
many options built in but it would be easiest to use and would be customized exactly for the Novartis
process and setup. Although the learning curve is low, there is also a high risk that users would use the
model without fully understanding the assumptions that go into it. To mitigate this risk, the use of the
model would have to be restricted to a few trained users and good documentation would be essential.
4.3.5 Software Selection
The following table (Table 3) is a summary of the analysis from above.
Table 3: Simulation Software Analysis
Based on this analysis, we decided to design and build a customized model in Excel. Based on
discussions with future users at Novartis, their main criterion was ease of use; they were concerned that
using one of the pre-designed software packages would require too much of a learning curve and they
would never allocate enough resources to get someone trained to use it effectively. Although another
model platform would have enabled more detailed analysis, this version of the model is more likely to be
used and will therefore be more effective in the long run.
5 Model Development
In the previous chapter, the model goals were finalized, assumptions were articulated, and the software
package was selected. Using that foundation, it is time to get into the details of model development. This
chapter first describes the overall layout of the model. From there, it describes the detailed setup of the
two main cost model sections. It explains the different types of analysis that can be completed, such as an
in-depth process analysis or a high-level product comparison. It also explains the meaning of the key
inputs that are sent to the model and the calculations and significance of the end results.
5.1 Model Layout
A diagram of the overall model follows below (Figure 7). As the diagram shows, there are two main
parts to the model: the Process Flow Cost Model and the Overall Cost Model.
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Figure 7: Cost Model Layout
Note: each box in the layout diagram represents a worksheet within the Excelfile
The model is separated in this way because there are two different levels of detail in the data and
stakeholders will be interested in different sets of information. For example, the Process Flow Cost
Model does just what its name suggests: it analyzes the process flow for a particular product. This section
is designed to get into the details of the manufacturing process. Specific parameters such as descriptions
of the raw materials consumed, the product concentration, and the step yields are all incorporated here.
The main outputs are the overall costs for materials used in one batch. The model also calculates the
amount of time each batch could (theoretically) take to process, although the actual processing time
usually ends up being longer due to other parameters such as resources and supply of cleaning materials.
This type of information is useful for employees in product development or perhaps for process engineers
working in the factory.
The second section, the Overall Cost Model also does what its name suggests: it pulls together all
elements of cost to provide an overall picture of the Novartis factory costs. This section takes some
inputs directly from the Process Flow Cost Model. The user adds additional inputs related to the
production plan and budget and then the model calculates the overall product cost. In this case, outputs
are not focused on a detailed analysis of the process flow. Instead, this model encourages users to
compare costs between products. It also helps users understand how process inputs impact overall (and
not just material) costs. Results from this model are summarized in a worksheet outlining each element of
costs as well as a Gantt chart that shows the approximate production schedule. Since it is higher-level,
this information would probably be more useful to a factory manager or a capacity planner.
Although these models are in two separate Excel files, they were designed to be used together.
Separating them into two excel files simply makes them less unwieldy to use; because different users are
responsible for providing different sets of inputs, separating the data into two areas allows users to focus
in their area of expertise. The diagram in chapter 4 (Figure 5) also shows how these costs can be
separated.
5.2 Process Flow Cost Model
This part of the cost model describes details of the production process. It allows users to input key
process parameters, which it then uses to calculate the processing time and material cost for the step. For
example, for the Protein A Chromatography step, the user inputs parameters such as resin capacity, resin
lifetime, and the diameter of the chromatography column. The model uses that information to calculate
the amount of resin needed for each batch.
5.2.1 Inputs
Users input this process information in the main "Process Flow" worksheet. Figure 8 below shows the
worksheet layout. This is a simplified view but each process step and several key process parameters are
listed. All calculations are done directly in this worksheet so they are simpler for users to follow. Since
the model is designed for a fed-batch monoclonal antibody (mAb) process, and this process is very
similar for most mAb's, the model can be modified relatively easily for new products by changing a step
from "Active" to "Inactive".
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Figure 8: Process Flow Layout
From these user inputs, the model summarizes how much of each material is used at each step.
It also needs to know how much each material costs per unit so it can calculate a total cost; the "Material
Input" worksheet is used for that. In this sheet, all materials are listed along with a unit price. 3 By
organizing the model in this way, the Material Input sheet only needs to be updated if a new material is
added or if a material price changes.
3 In the context of this model, "materials" include three things: raw materials, resins, and (non-resin) consumables.
Process
Flow
5.2.2 Outputs
Once all inputs are provided, the model calculates and summarizes the final product mass as well as the
cost for materials used at each step. It then summarizes this information in a table (Figure 9) that will be
fed into the Overall Cost Model.
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Figure 9: Process Flow Summary Table
Material costs and processing times are the only parameters that are significantly affected by the process
flow. Therefore, once this output table is compiled, the Overall Cost Model can be effectively separated
from the process details. That way, if people with different interests are using the model, the process
expert can update this part of the model and the other user (such as an upper level manager or a finance
employee) can update the other part.
5.3 Overall Cost Model
As the previous section explained, the Process Flow Cost Model analyzes the process flow for a given
product. Once the user inputs the key process parameters, the model calculates how much will be spent
on the various material types. This information is useful to verify how much the factory is spending on
materials right now, but its use is not constrained to the current state. By inputting hypothetical sets of
process parameters, the model can be used to support recommendations to the factory on future parameter
selection.
The Overall Cost Model takes the materials data and expands on it. The main output from this model is a
summary of overall costs. In particular, an employee can use this model to analyze scenarios and get a
prediction of what each one will cost. For example, what if the number of batches run per week changes
from one to two? Or what if a change to the process allows throughput time to decrease by three days?
The model allows employees to explore different options without any risk.
5.3.1 Inputs
Several sets of inputs are necessary for this model to work: material costs (which are all variable), non-
material costs (including both fixed and variable), and details about the scenario to be run. The input
method for each of those is explained here.
Inputting Material Costs
The first information required is the materials costs that were already calculated using the Process Flow
Cost Model. A user can either type these in or can link directly to the Process Flow Cost Model. Also,
depending on user preferences, material costs can be entered per process step or as an overall figure.
Either method is fine; the choice will just slightly impact which results can be calculated.
Inputting Non-Material Costs
The next required set of inputs is information about all other costs in the factory: how much is spent in a
baseline year? The cost predictions in the model are extrapolated from this baseline information. This
financial information (referred to as Period Cost Expenses, or PCE at Novartis) could be entered in many
different formats. For this model, cost data are entered in a grid (see Figure 10) that divides costs by
different criteria. The column labels, or "cost categories", are classifications for the type of expense in
question, and the row labels, or "cost types", refer to the group within Novartis that incurred the expense.
This division is a method of analysis that Novartis Finance already uses so it is an easy input method for
them to employ.
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Figure 10: Novartis Budget Information4
The exact layout of these inputs is relatively unimportant as long as it is clear which costs are variable and
which are fixed. In this particular layout, the variable costs are isolated in just eight of the squares, which
are highlighted for emphasis. They can be summarized as follows.
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Figure 11: Variable Costs
When costs for a scenario are calculated, these variable costs are the only ones that are revised. These
costs are modified and predictions for the scenario cost are calculated using the assumptions described in
the previous chapter. The remaining PCEs are all fixed. This means that they are not expected to change,
regardless of the scenario, so their values are taken directly from this table. There are many more fixed
costs than variable costs but variable costs are still large enough to have a significant impact on the
results.
Inputting Scenario Information
The information entered so far has been focused on cost data that are required before analysis can begin.
The final information required from the user is specifications for the actual analysis to be run. This
4 All tables and figures have been modified to protect the confidentiality of Novartis data. Numbers shown in these
figures are meant to explain the concept but they are not representative of actual results.
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information centers on the type of products and the duration of campaigns that the factory will be running.
After all of this information is gathered, the model is able to analyze the production process given all of
the process parameters and predict the actual production costs. As discussed several times, the main goal
of this model is to predict the cost in a hypothetical future scenario. And, as discussed, the main items
that go into this overall product cost are any materials consumed, any variable personnel or utilities, and
any overhead (that is, fixed costs) allocated to the product. Most of those data have already been
compiled; the previous steps reviewed methods for inputting the cost per batch and the overhead costs.
The final step is to input any parameters that will impact the total variable costs or the allocation of
overhead to the different steps.
Since the total variable costs depend on the number of batches, that will be a key parameter. The user
inputs the number of batches per campaign along with the other scenario information. The overhead
depends on the amount of time a product is using the factory. Since each campaign overlaps slightly the
time dedicated to a campaign is defined as the time from the end of the previous campaign to the end of
the current campaign. The following figure shows the inputs and several built-in calculations that are
necessary to complete this calculation:
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Figure 12: Sample Scenario Input Area
More descriptive definitions of all of these parameters are included in Appendix 1, but the figures below
define them graphically.
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Figure 13 : Visual Representation of Scenario Input Parameters
The calculations that are built into the model all depend on the inputs from the user. These are the
calculations used to calculate those parameters:
Equation 1: Batch Cycle Time
Batch Cycle Time =7 days/week# Batches/week
Equation 2: Campaign Duration
Campaign Duration = (# batches per campaign - 1) * Batch cycle time + Batch TPT
Equation 3: Time Dedicated to Campaign
Time Dedicated to Campaign = Campaign duration + (Changeover time +
duration of bottleneck step- batch TPT
The time dedicated to the campaign is the key used to allocate overhead costs to different products;
overhead is allocated to a product proportionally to the percentage of the year that the factory is dedicated
to running that product.
The user can enter data for up to 10 campaigns and can analyze a wide range of options with each
scenario. For example, the data could be used to analyze the exact production plan for the coming year.
It could also be used to test a small change to the plan, to look at just one product, or to compare 10
campaigns with different parameters on each one and to do a sensitivity analysis. More information about
the output data is included in the next section.
5.3.2 Outputs
The three areas described above (material costs, PCEs, and analysis details) are the only places where
inputs are required. Once these inputs are complete, the output is automatically calculated. It can be
found in the "Output" and "Gantt Chart" worksheets.
Gantt Chart
The Gantt Chart worksheet is mostly used as a double check to ensure that all parameters were entered
correctly. Based on the inputs that were entered, this worksheet produces an approximate production
plan. If a campaign is much shorter than expected or the batches are running too quickly, then the user
knows to go back and check the inputs. The diagram below is representative of what the Gantt chart
looks like for a sample production plan, where each cell represents one day.
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Figure 14: Sample Gantt Chart
Summary of Costs
The output table can easily be modified depending on the specific results the user is looking for, but the
current table includes a wide variety of parameters that should apply to most situations.
In Figure 15, you can see an example of some key output information with three different views of the
same costs. Depending on the information that is required, a different view may be more relevant. For
example, the first table breaks costs into fixed and variable components, whereas the second table breaks
them down by cost type and category.
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Figure 15: Cost Summary Data
Campaign Summary
The following figure shows the calculation of costs per campaign for several different campaigns. In this
example, each campaign has a different cycle time. Fixed costs are allocated to campaigns based on the
percentage of the year that they occupy the factory and variable costs all depend on the number of batches
that are run.
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6 Research Analysis
The previous sections explained the context for the model and the steps leading to its development. This
chapter starts by reviewing the accuracy and precision of the model; how exact are the results expected to
be? The rest of the chapter looks at several case studies to showcase certain conclusions the model helps
make clear.
6.1 Model Verification and Data Sources
Before getting into the verification of the model, it is important to remember what the standard is. The
goal of the cost model is to be at least as accurate as the standard cost models that are in use today,
while also being easier and more intuitive to use. This means that the gold standard for verifying this
model's accuracy will be the standard financial models in use today. Therefore, when a cost is calculated
"exactly", then it is equal to the standard financial model to which it is being compared. Comparisons for
some cost components are straightforward since the new model uses some data directly from the finance
group. However, other cost components will have some level of inaccuracy in them, and still others will
require more verification at Novartis before the model can be used extensively. This section explains the
data sources for the model, the expected accuracy of the results, and areas where there is room for
improvement.
In the Method chapter, Figure 5 summarized the steps required to calculate the overall product costs: (1)
calculate material cost components; (2) calculate other variable cost components; (3) calculated fixed
overhead cost components; (4) determine how to allocate the fixed costs across products; and (5) add each
component together to compute the overall cost. The accuracy of the model depends on both the accuracy
of the data inputs (items 1 through 3) and the calculations built into the model (items 4 and 5). The
following sections describe the process for model verification in each of these categories.
6.1.1 Data Inputs: Material Cost Components
Results for each section are calculated differently since inputs come for a variety of data sources. These
sources include locations such as the SAP Materials Requirements Planning system, the factory's budget,
tracking spreadsheets from factory planners, standard operating procedures, and more. In the first area of
costs, material costs, the data sources are especially varied.
The materials consumed during production include Raw Materials, Resins, and Consumables. These are
all variable costs and change directly with the number of batches. The user initializes the model by
inputting the list of materials used for a product. The model then predicts the actual cost and quantity
consumed for each material based on the process parameters the user has selected.
It is relatively simple to verify baseline results for raw materials and resins. The Novartis SAP system
already calculates raw material costs for each batch that is run so model results are just compared to those
pre-calculated numbers. It is also possible to calculate the resin cost exactly since there are only three
resins used for each product and only a few parameters impact the resins' costs. When the model is used
to predict process changes, raw material costs are a little harder to confirm. One of the model's main
benefits is its ability to predict the cost impact of process changes, and the reason this is such a benefit is
that no system is capable of doing this today. Luckily, in most cases only a few materials make up the
large majority of the raw material cost, so the approximate accuracy of those numbers can be verified by
focusing on those materials.
For consumables, there is no easy way to verify the results. Today, each group in the factory adds up the
amount they expect to spend based on the amount they spent last year, adjusted to the best of their ability
based on their knowledge of the process. In historical cost models, consumable costs are not impacted by
changes to process parameters. The total consumable cost is prorated across all products based on the
number of batches that are run. This new model adds in much more detail and allows the user to see how
changes to the process will impact those consumable costs. This ability is extremely useful, but since it
was not done before it is harder to verify. For now, consumable costs are verified individually based on a
consumable-tracking spreadsheet developed by a Novartis employee. Like raw materials, there are only a
few consumables that make up a large percentage of the costs so verification can focus on these items.
Consumable-tracking is an area that Novartis plans to make more robust in the future but the current
approximation in the model is a step in the right direction.
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As shown in this section, some analysis can be fine-tuned in the future but there are still steps that can be
taken to verify each datum that is entered.
6.1.2 Data Inputs: Non-Material Cost Components (both Variable and Fixed)
The previous section dealt only with materials that were actually used during production. This section
deals with all non-material expenses at the site. These costs include items from labor to depreciation to
utilities and more. While the material costs were entirely variable, these costs are not so straightforward.
Some (like overhead and depreciation) are entirely fixed and independent of the number of batches, while
others (like personnel and utilities) have both fixed and variable components. The following paragraphs
provide verification for the non-material cost calculations.
Since many of these costs are fixed in the short term they can be grouped together; there are only a few
costs that required additional analysis and verification. More details follow below in Table 5.
Table 5: Verification of Non-Material Costs
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6.1.3 Cost Allocation Parameters
The previous sections discussed all costs related to a production campaign. This area addresses the
calculations used to allocate costs to different products. Since the calculations used for this cost model
are the same as those used in the finance group for previous models, the allocation parameters should be
identical.
Table 6: Cost Allocation Parameters
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6.1.4 Overall Costs
Once the costs are calculated and allocated, the final step is to calculate overall results. If the individual
cost components are verified, then the overall cost is just a matter of adding up each component. This
was verified with several sample products and the models were shown to match. This confirms that the
new cost model uses the same calculation method as the old version, so when the same assumptions are
used they should provide the same results.
6.2 Research Analysis
The last section showed how the cost model can give results that are comparable to or more accurate than
the current standards used for predicting costs. The real benefit from the model comes in the way it is
used; this model should be easier to use, faster to setup, and more intuitive to understand than the current
method. This section looks at some questions that commonly arise in the pharmaceutical industry and
shows how the model helps answer them. It also shows how important it is to have a holistic view of
costs and other metrics at a site. The analysis starts by examining some general results from the model
calculations, and then several case studies are examined that show the sensitivity of costs to key input
parameters.
6.2.1 Results
Once the model is initialized with input data for a particular product, a wide variety of results and metrics
are immediately available. If any input parameters (such as the number of batches per week or the yield
at a given process step) are changed, then the model results update automatically. It is important to
remember that results are calculated for a specific product and are dependent on the assumptions and
parameters that are used. The results provided in this section use data for a representative Novartis
product to give examples of ways in which the model can be used.' This section starts by looking at a
breakdown of costs for a specific product. It continues with analysis of the overall product cost.
Cost Overview
One of the first questions managers are curious about is "where do we spend most of our money?" The
following charts (Figure 17 and Figure 18) show how costs are broken down within a given product.
s The scale in these results has been removed to protect confidentiality of Novartis data.
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Figure 17: Overall Product Costs by Cost Type - View 16
Figure 18: Overall Product Costs by Cost Type - View 2
(Materials vs. Overhead and Direct vs. Indirect)
As the charts show, variable costs - which include materials and variable overhead - are actually a small
component of overall costs. Most of the factory budget is used for longer term expenses such as non-
temporary personnel and depreciation. After a year or more some of these expenses could be reduced,
and the cost structure might also change if production is moved to a new factory, but for now the fixed
6 This specific scenario assumes that four batches were run during a campaign.
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costs cannot be changed. Likewise, direct costs - those costs that can be attributed directly to a process
step without being allocated - are a smaller part of the budget than indirect costs.
These results suggest that factory employees should only be held responsible for a relatively small
percentage of their budget since those are the only costs they can influence. Upper level management
should work with the managers within the factory to initiate larger changes that can reduce fixed overhead
in the longer term.
This also suggests that it is very important to design incentives and performance metrics that are tailored
to the specific goals of each level of the organization. For example, while the factory manager can decide
to hire more employees or to run more products, the shift supervisor is more focused on the amount of
extra resin they decide to hold in stock before a given campaign. If the shift supervisor's performance
metrics are largely tied to labor utilization rates, he may not work as efficiently as possible because this is
not something he can control. By designing metrics that align with achievable targets, an organization
can provide stronger incentives for groups to improve.
The next several paragraphs discuss the cost breakdown for the materials and for the direct costs in more
detail.
Material Costs by Type and Process Step
When looking at process development, material costs are one of the areas that can be optimized and
improved. In particular, there are a few key materials that end up costing a large amount of money for
each batch. See Figure 19 to understand how the material costs are broken down throughout the process
for this particular product.
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Figure 19: Material Costs by Process Step
The graphs show how material costs are focused in a few specific steps. In particular, the raw material
for the largest bioreactor, the resin at the Protein A chromatography step, and the filter for the
nanofiltration step all add significantly to the costs. If managers are trying to make reductions to their
material costs, they probably should not focus too much on improvements during other steps; honing in
on these three areas is likely to give them the highest potential return.
Direct Costs by Process Step
Only a few costs in a factory can be related directly to a specific process step. For example, it is clear
where each material is used during the process flow but groups like quality control and finance support
the entire factory. To charge a process step for wages of employees in the quality group, those wages
would have to be allocated using an allocation key. These costs are called indirect costs since there is no
direct link between them and the process. These graphs show which costs are direct and how those costs
are broken down across process steps.
Figure 20: Direct Costs by Process Step
When a factory manager looks at costs for a specific step, the direct costs are the ones he is most likely to
be able to control. Again, comparisons like this help employees focus on potential areas for
improvement. For example, for this product it looks like direct labor is highest at the large bioreactor,
whereas materials costs are high at many of the steps.
6.2.2 Case Studies
The results above help users understand what costs look like in a specific scenario. To get more complex
insights, sensitivity analyses can be conducted to understand the impact of one parameter more
completely. This section looks at several common parameters to shed light onto their behavior. It also
showcases the type of studies the model can be used for.
The first two analyses are focused on changes to the process. The final two are focused on changes to the
overall product parameters.
Increasing Titer with Fermentation Time
A common question within biotech production is the impact that a change to the titer would have on
manufacturing costs. Knowing this answer could potentially have an enormous impact on production
costs because the development organization could tailor the titer in a way that optimizes production.
Usually, changing the titer is possible through a tradeoff with fermentation time; for example, increasing
the titer also requires higher fermentation times. The analysis in Figure 21 looks at several combinations
of the two parameters.
Figure 21: Impact of Titer on Cost per Gram
Scenario 1 has the lowest titer and fermentation time; #4 has the highest titer andfermentation time
This graph shows how increasing the titer for this product is probably a beneficial decision even if it
means the fermentation time has to increase.
There are several items to note in this graph. First, there is the bend in the lines at scenario #2. This is
the point where the bottleneck in the process changes from the upstream processing steps (for scenarios 1
and 2) to downstream (for the remaining scenarios). Second, the variable cost per gram does not actually
improve very much. This is because the cost for materials (especially resins) increases significantly per
batch as the titer increases, thus obscuring some of the gain achieved by improved yields.
Increasing Resin Cost with Binding Capacity
Suppose that a more expensive resin was found that could purify more grams of product per liter of resin.
How much more efficient would the resin have to be in order to make the switch worthwhile? This
scenario assumes that the resin cost will increase by 20%. It then looks for the percentage increase in
binding capacity that would be required to justify this change.
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Figure 22: Impact of Resin Parameters on Costs
This graph shows that a more expensive resin would pay off once the binding capacity improved by at
least 20%.
This graph has a step pattern which may not be immediately intuitive. This pattern is related to the way
that resins are loaded into a container called a chromatography column. Before running a batch, a column
is filled with resin. The product batch is split up and run through the column in cycles. The amount of
product allowed per cycle is proportional to the binding capacity of the resin; after that binding capacity is
reached the resin has to be cleaned before being used again. The amount of resin per column is fixed
since the column has to be full whenever it is used. Therefore, the amount of resin needed per batch is
determined by how many cycles are required. For example, if a product requires 200L of resin but the
chromatography column is 150L, the product would still have to run through the two full cycles. In this
analysis, the number of required cycles per batch reduces once the binding capacity hits 120% of its
baseline and then again at 170%.
Variable Costs and Idle Capacity
Chapter 4 showed how allocating idle costs to the products that are run in a factory could distort the
perceived costs. The following example shows two different ways of analyzing a decision. In this case,
the factory is trying to understand how their costs will change if they run four products during the year
instead of three. The first set of graphs compares the scenarios with idle time included; the second
scenario reports idle time separately.
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Figure 23: Cost Comparison: 3 vs. 4 batches, Idle Costs Included
Figure 24: Cost Comparison: 3 vs. 4 batches, Idle Costs Separate
In the first analysis, where idle costs are included in the overall product cost result, increasing to four
batches makes it look like the cost per batch has significantly decreased. In the second analysis, the costs
are more accurately represented; the cost per batch has not changed substantially but the costs for idle
time have gone down. These results may seem intuitive but the first analysis is frequently used because
companies know that someone has to pay for the idle time. However, allocating idle time across the
products initially obscures the true cost. Managers have to be careful to understand exactly where their
results come from before making impactful decisions, and this cost model helps them do just that.
Capacity Utilization and Value Stream Analysis
Look again at the first graph in Error! Reference source not found.. If you add another campaign that
costs the same as the first ones, how much additional money is the factory actually going to spend? The
most immediate answer is that the value of the campaign is equal to the size of that first blue bar.
However, this answer is incorrect; that blue bar includes many fixed costs in addition to the variable
costs. This challenge demonstrates why it can be useful to look at value stream instead of product-
specific costs.
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Figure 25: Change in Cost as Capacity Utilization Increases
This chart shows how little costs actually increase as additional campaigns are added. This chart does
include one significant assumption: for the scenario simulated here, no additional capacity would be
needed to manufacture the additional products added to the factory. If a new factory is needed, then new
capital investment will have to be made, which does end up impacting costs. However, that cost would
impact your value stream analysis as well, which would make your factory cost drastically increase at a
certain production level. While capacity is standing idle, increasing utilization is usually fairly
inexpensive. However, whether capacity is available or not, looking at the overall factory costs instead of
focusing on the product details can be a useful tool.
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7 Conclusion
This cost model helps make the Novartis financial results much easier for internal management to
understand and take action on. For example, the graphs in chapter 6 make it clear that, for the product
examined in this study, raw materials are a relatively unimportant part of costs. Or, from a broader view,
fixed costs are a large percentage of costs overall so there should be efforts to reduce those in the long
term; in the short term the most impactful materials to focus on are the first chromatography resin or the
nanofilters.
The model can also help predict the cost impact of changes to the process flow or product mix. As shown
here, adding more batches is not a large expense when a plant has extra capacity, but can be much more
so as utilization goes up. The same was true for titers; in some situations, this is one of the most
important parameters, but in others it was not at all.
However, the primary benefit of this model is not the specific results that were reported here. Each
scenario that was analyzed has a common thread: straightforward questions were asked that led to clear
answers. Managers should use this to increase their understanding of the process and to develop intuition
about their financial results. For example, since the model connects financial costs to operational
parameters (like the example that showed the impact of fermentation time and titer), factory managers can
see how their decisions impact costs. By setting up the model with inputs from Finance, Process
Development, and Manufacturing, each of these stakeholders can see how their areas interact and they
can work more closely together. A model of this type will not have all the answers, but the results will be
usable and actionable and employees will be able to connect the results directly to their own work.
7.1 Applicability to other Companies and Industries
The problems described here are applicable across industries. Each company and industry has a different
cost structure; for example, some companies have a much higher percentage of variable costs with lower
overhead, whereas others spend almost no money on materials. However, the idea of visualizing costs in
an easy to use way is universal.
The most immediate connection is other factories within Novartis that produce biologics. For these sites,
the model could be used with minimal modifications to model and predict factory costs. If this concept
were to be extended and used in other industries, the model layout would have to be recreated since the
process flow would change. Nonetheless, the concepts and steps taken to create the model would be the
same.
7.2 Potential Future Research
There are several areas mentioned in this thesis that would be worthwhile for further research. Several of
them are described below.
Model Improvement
This model predicts results based on the assumptions it is given. As described earlier, some of the
assumptions, such as the description of labor costs, are oversimplifications. To improve the accuracy and
robustness of the model, additional analysis could be done on these assumptions to improve their level of
detail.
Model Implementation
The model development is complete but it has yet to be fully implemented within the Novartis factory. In
order to make this happen, additional verification of the model should be completed and shared with the
various stakeholders to increase the level of confidence in the model results. Once that is complete, the
model can start to be used alongside some of the currently utilized cost models. Over time, this new
model can start replacing the other models and improving the level of analysis that can be done.
Connect to Lean Business Management Initiative
A different group at Novartis is already investigating many of the concerns raised in this thesis. For
example, they are looking at ways to align key process indicators across different levels of the
organization by creating linkages between the different goals. They also plan to encourage the use of
combined financial and operational metrics to aid decision making. This project has a wide breadth and a
several-year time horizon but the goals are very closely related to the goals described for this model. As
the Lean Business Management group starts implementing pilot programs in several factories, they can
look at ways to use the model's data to help with their goals.
7.3 Conclusions
The goals stated for this project were to create an easy to use method that would make cost results and
cost drivers easier to understand. Several key conclusions can be drawn from this model's development
and use:
* A cost model can simplify financial analysis: Managers have to keep track of a wide variety of
information every day and they do not want to spend unnecessary time chasing down cost data.
A cost model that simulates the production process can simplify results and make them more
accessible to employees. A model like this is not restricted to use in just one area; it could also be
used to simplify financial decisions in different divisions of the company.
* Idle costs can be misleading: These costs should be listed separately so employees can
understand their true impact. When idle costs are wrapped up in the product cost, it is easy to
assume that a product costs more than it really does. By separating them out, employees are able
to understand the true expenses for a given product.
* Costs are often dominated by several critical components: When costs are broken down by
type, there are actually only a few elements that comprise a very large percentage of overall costs.
In addition, when employees focus on the costs they can control, these elements (such as resins
and nanofilters) are even more significant. Employees can have an immediate impact on costs by
focusing on reducing these elements.
* Operational and financial metrics should be used together: This thesis looked at several
examples where either operational or financial metrics could be misleading when viewed on their
own. For example, while fixed production costs do affect a product's cost, the overall financial
impact that these fixed costs have varies depending on the factory's capacity utilization. By
modeling costs and operations side by side, these conflicts can be understood and mismatched
incentives can be avoided.
The results and analysis presented here provide insight into cost drivers for one particular product, but the
findings are much more widely applicable. By using these recommendations as guidelines, Novartis can
use this cost model to help reduce their costs and make more effective decisions.
Appendix 1 - Worksheet Layout: Details of a Process Step
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Appendix 2 - Worksheet Definitions
Definitions of many of the model parameters are included here.
Key Process Flow Parameters
This first set of tables includes parameters used in the Process Flow Cost Model.
Initial State
Process name
Process description
Incoming volume
Incoming product mass
Incoming titer
Key Inputs
Step yield
Change in volume during step
Preparation time
Processing time
Cleaning time
Key Outputs
Outgoing volume
Outgoing product mass
Outgoing titer
Description
Title of the process step
Description of the process step (optional)
In USP, this is a user input: it is not always necessary to put the entire volume from
one bioreactor into the next one.
In DSP, this is equal to the outgoing volume from the previous step.
In USP, this field is not needed until the final bioreactor (either 2500 L or 14500 L).
In DSP, this is equal to the outgoing mass from the previous step.
In USP, this field is not needed until the final bioreactor (either 2500 L or 14500 L).
In DSP, this is equal to the outgoing titer from the previous step.
This is usually input by the user. However, in a few cases (eg centrifugation) the
number of discharges will impact the yield so it is calculated within the model.
Calculated based on the volume of buffer and media added (or lost) during the step.
Amount of time used to prepare for a process step.
This is currently a user input and is not used to calculate the batch throughput time.
Amount of time needed to process a batch at one step. This is input for USP and
calculated in DSP.
(This field should be updated; the values in it are approximate for now)
Amount of time used to clean up from a process step.
This is currently a user input and is not used to calculate the batch throughput time.
Calculated based on the incoming volume and the change in volume during the step.
Calculated from the incoming mass and the step yield
Calculated from the outgoing volume and mass
Other Inputs
There are many possible "other inputs".
Some examples are: filter part number, chromatography column bed height, resin binding capacity, etc.
For details and definitions, see the SOP.
Processing Details
There are also many possible "processing details".
For details and definitions, see the SOP.
Extra Section (If needed)
This is used for any additional consumables or parameters that were not included elsewhere.
Material Summary
All of the results from above are summarized in this section.
When the "Calculations" sheet summarizes the materials that are used, it pulls the data from this "Material
Summary" section
Key Overall Cost Parameters
This table includes a list of parameters from the Overall Cost Model.
Camnel n# 8 Sel-explanatory
roductname Self-explanatory
batchesper campaign Self-explanatory
gramsperbatch The final# grams per batch (after accounting for yield loss and batch success rate)
atchTPT Throughputtime; timefrom the beginning to end of one batch. See below.
3alchesperweek (dudng campaign) # batches that can be started (and finished every week).
# days from end of bottleneck step of last batch of a campaign to beginning of
amnpaign changeovertme bottleneck step in first batch of next campaign. Equals the number of days between
___________________________the beoinnino of the batches. See below.
ration of hleneck stop Self-explanatory
ttch 2 r time# days between batch starts. Equals 7 days / # batches perweek. See below.
duration # days a campaign actually runs (from beginning to end). See below.
# days allocatedto a campaign; calculated from end of previous campaign to end
time dedicatedto campaign (wo shuidown) of current campaign. Conceptually equal to the number of days that running onecampaign prevents youfrom running another campaign in yourfactory. Usedto
determine how much overheadto allocate to each campaign. See below.
wmatst codprbatch) Can calculate using process flow sheet or can get from finance group.
os rba) Can calculate using process flow sheet or by using'help toolbox'tab, or can getfrom finance group.
) an calculate using process flow sheet or can get an approximation from financeSgroup.
rransfercosts (on top of base quality& MT Any additional campaign costs can be added here.
osts)in
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